Ravelo A, Myers K, Brumble R, Bussberg C, Koffman B, Manzoor BS, Biondo JML, Mansfield C. Patient preferences for chronic lymphocytic leukemia treatments: a discrete-choice experiment. Future Oncol. 2024 May 22;1-12. doi: 10.1080/14796694.2024.2348440
Furqan M, Karanth S, Goyal RK, Cai B, Rombi J, Davis KL, Caro N, Saliba T. Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study. Future Oncol. 2024 Apr 17. doi: 10.2217/fon-2023-1064
Fliser D, Lorenzo MM, Houghton K, Ainsworth C, Blogg M, Gonzalez de Antona Sanchez E, Portles J. Real-life anemia management among patients with non-dialysis-dependent chronic kidney disease in three European countries. Int J Nephrol Renovasc Dis. 2023 Apr 13;16:115-29. doi: 10.2147/IJNRD.S401598
Paik PK, Goyal RK, Cai B, Price MA, Davis KL, Derrien Ansquer V, Caro N, Saliba TR. Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib. Future Oncol. 2023 Jan;19(3):217-28. doi: 10.2217/fon-2022-1133
DeBusk K, Abeysinghe S, Vickers A, Nangia A, Bell J, Ike C, Forero-Torres A, Blahna MT. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis. Future Oncol. 2021 Nov;17(33):4635-47. doi: 10.2217/fon-2021-0742
Singal AG, Nagar SP, Hitchens A, Davis KL, Iyer S. Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA. Future Oncol. 2021 Jul;17(21):2759-68.
Mansfield C, Myers K, Klein K, Patel J, Nakasato A, Ling YL, Tarhini AA. Risk tolerance in adjuvant and metastatic melanoma settings: a patient perspective study using the threshold technique. Future Oncol. 2021 Jun;17(17):2151-67. doi: 10.2217/fon-2020-1193
Tripathy D, Blum JL, Rocque GB, Bardia A, Karuturi MS, Cappelleri JC, Liu Y, Zhang Z, Davis KL, Wang Y. POLARIS: a prospective, multicenter, noninterventional study assessing palbociclib in hormone receptor-positive advanced breast cancer. Future Oncol. 2020 Nov;16(31):2475-85. doi: 10.2217/fon-2020-0573
Vassilev ZP, Soriano Gabarro M, Kaye JA, Saltus CW, Riedel O, Scholle O, Mehtala J, Korhonen P, Garbe E, Zong J. Incidence of second primary malignancies in metastatic castration-resistant prostate cancer: results from observational studies in three countries. Future Oncol. 2020 Sep;16(25):1889-901. doi: 10.2217/fon-2020-0315
Mansfield C, Ndife B, Chen J, Gallaher K, Ghate S. Patient preferences for treatment of metastatic melanoma. Future Oncol. 2019 Apr;15(11):1255-68. doi: 10.2217/fon-2018-0871
Darden C, Mitra D, McSorley D, Davis K, Band J, Iyer S. Treatment satisfaction in women receiving palbociclib combination therapies for advanced/metastatic breast cancer. Future Oncol. 2019 Jan;15(2):141-50. doi: 10.2217/fon-2018-0531
Young L, Dong O, Wiltshire T, Kypzyk K, Guenzel N. MC4R polymorphism associated with antipsychotic-associated weight gain. Poster presented at the 11th Congress of the International Society of Nutrigenetics and Nutrigenomics Annual Meeting; September 17, 2017. Los Angeles, CA. [abstract] J Nutrigenet Nutrigenomics. 2017; 10:121. doi: 10.1159/000480052
Dong OM, Suzuki O, Howard R, Jamieson K, Pointer M, Kohlmeier T, Wiltshire T. Using targeted next-generation sequencing as a cost-efficient method to characterize the genetics of salt sensitivity. Poster presented at the 11th Congress of the International Society of Nutrigenetics and Nutrigenomics Annual Meeting; September 18, 2017. Los Angeles, CA. [abstract] J Nutrigenet Nutrigenomics. 2017; 10:100. doi: 10.1159/000480052
Henderson GE, Cadigan RJ, Edwards TP, Conlon I, Nelson AG, Evans JP, Davis AM, Zimmer C, Weiner BJ. Characterizing biobank organizations in the U.S.: results from a national survey. Genome Med. 2013 Jan 25;5(1):3. doi: 10.1186/gm407
Braun L, Sood V, Hogue S, Lieberman B, Copley-Merriman C. High burden and unmet patient needs in chronic kidney disease. Int J Nephrol Renovasc Dis. 2012 Dec 1;5:151-63.
Melendez J, Galli I, Boric K, Ortega A, Zuniga L, Henriquez-Roldan CF, Cardenas AM. Zolpidem and triazolam do not affect the nocturnal sleep-induced memory improvement. Psychopharmacology (Berl). 2005 Aug;181(1):21-6. doi: 10.1007/s00213-005-2228-0
Dykstra LA, Granger AL, Allen RM, Zhang X, Rice KC. Antinociceptive effects of the selective delta opioid agonist SNC80 alone and in combination with mu opioids in the squirrel monkey titration procedure. Psychopharmacology (Berl). 2002 Oct 1;163(3-4):420-9.